医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Provides Further Information about Its New Business Venture with Teva

2015年12月28日 AM08:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan & JERUSALEM

Takeda Pharmaceutical Company Limited (TOKYO: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) today made the below follow-up announcement regarding the overview of their new business venture in Japan, which was initially disclosed on November 30, 2015 in the press release titled, “Teva and Takeda establish unique partnership to meet the wide-ranging needs of patients and growing importance of generic medicines use in Japan”. [http://www.takeda.com/news/2015/20151130_7215.html]

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151227005006/en/

  • The new business venture, to be established in or after April 2016, will deliver Teva’s high-quality generic medicines and some of Takeda’s long listed products to patients and healthcare professionals in Japan, leveraging Takeda’s corporate brand and unique distribution network in Japan and Teva’s wide product portfolio and cutting-edge business efficiency.
  • The major long listed products of Takeda to be transferred to the new business venture in FY2016 are BLOPRESS, TAKEPRON and BASEN. Total sales of the products to be transferred in FY2016 were 125 billion yen in FY2014, which was 7% of Takeda’s global revenue. As a result of the transaction, Takeda’s FY2016 revenue is estimated to decrease by approximately 50 billion yen, based upon current assumptions. LEUPLIN remains at Takeda, as a product of Takeda Oncology.
  • The new business venture, to be owned 51% by Teva and 49% by Takeda, will consist of Teva Takeda Pharma and Teva Takeda Yakuhin. The details of establishing these companies by an absorption-type company split are outlined in a separate release issued by Takeda to file to the Tokyo Stock Exchange: “Takeda Announces Details of New Business Venture with Teva in Japan – Splitting off (absorption-type split) of Takeda’s Long Listed Products Business and its Subsequent Succession by Teva” (herein called “Takeda’s TSE Filing”). [http://www.takeda.com/news/2015/20151228_7258.html]
  • Takeda anticipates that the transaction will be both EPS and cash flow accretive in FY2016 and over the long-term, due to growth of the generic business and the addition of products from Takeda and Teva to the new business venture. Some additional details about the financial impact of the transaction are outlined in Takeda’s TSE Filing, and all will be incorporated into Takeda’s FY2016 forecast which will be communicated in May 2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151227005006/en/

CONTACT

For Takeda Pharmaceutical Company Limited:
For
investors:
Noriko Higuchi, +81 3-3278-2306
noriko.higuchi@takeda.com
For
media:
Tsuyoshi Tada, +81 3-3278-2417
tsuyoshi.tada@takeda.com
or
For
Teva Pharmaceutical Industries Ltd.:

For investors:
Kevin
C. Mannix, +215-591-8912 (United States)
Ran Meir, +215-591-3033
(United States)
Tomer Amitai, +972 (3) 926-7656 (Israel)
For
media:
Iris Beck Codner, +972 (3) 926-7687 (Israel)
Denise
Bradley, +215-591-8974 (United States)
Mikiko Yamada,
+81-52-459-2001 (Japan)

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • FDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
  • TL PLASTIC SURGERY in South Korea, the Best Choice for Your Satisfying Breast Augmentation Surgery
  • Ascendia Pharmaceuticals宣布其治疗急性冠脉综合征的ASD-002项目获颁一项新专利
  • 年次世界患者安全・科学・技術サミットで初めて米国外向けにHDライブストリーミングを実施へ
  • Accelsiors CRO Expands Global Footprint